最近的 ICE3 乳腺癌冷冻消融试验显示，成功率高达 98%，与保乳手术类似。然而，ICE3 和其他已发表的研究没有区分治愈性治疗和姑息性治疗，也没有定义患者特定的治疗目标。我们试图确定乳腺癌根治性和姑息性乳房冷冻消融术在满足手术目标和患者特异性治疗目标方面的成功率。我们对 2021-2024 年期间接受乳房冷冻消融术的乳腺癌患者进行了回顾性分析。乳腺放射科医生在超声或 MRI 引导下使用局部麻醉和氩气冷冻探头进行门诊冷冻消融。分析了患者人口统计、转诊指征、肿瘤特征、手术细节和影像学随访结果。冷冻消融被分类为治愈性或姑息性。治疗成功被定义为手术和患者特定治疗目标的实现。对 29 名 N0M0 (n = 25)、N1M0 (n = 2)、N2M0 (n = 1) 和 N0M1 患者的 34 个病灶进行了乳房冷冻消融术(n = 1) 疾病。大多数肿瘤为浸润性导管癌 (IDC)、低至中度恶性、雌激素受体 (ER) 和孕激素受体 (PR) 阳性且 HER2 阴性（23 个肿瘤，68%）。治疗性冷冻消融的肿瘤大小范围为 0.4-1.9（中位数 0.8）厘米，姑息性冷冻消融的肿瘤大小为 0.6-6.0（中位数 1.3）厘米。在 27 名进行影像学随访的患者中，14 名患者（14 个肿瘤）消融获得治愈，13 名患者（18 个病灶）获得姑息治疗。影像学随访时间范围为 3 至 26（中位数 16）个月，27 名患者中的 22 名患者和 32 个肿瘤中的 25 名患者的影像随访时间> 12 个月。并发症仅限于2例皮肤冻伤，1例轻度，1例中度。 14 名治愈患者中的 13 名以及所有 13 名姑息性冷冻消融患者均取得了治疗成功。我们的研究定义了治愈性和姑息性乳房冷冻消融术的治疗成功，表明乳房冷冻消融不仅实现了手术（技术），而且实现了患者特定的治疗目标，且没有显着影响并发症，并可作为将乳房冷冻消融术纳入乳腺癌患者治疗的指南。版权所有 © 2024 大学放射科医生协会。由爱思唯尔公司出版。保留所有权利。

Recent ICE3 trial of breast cryoablation for breast cancer demonstrated 98% success rate, similar to breast-conserving surgery. However, ICE3 and other published studies did not differentiate curative from palliative treatment nor define patient-specific treatment objectives. We sought to define treatment success of curative and palliative breast cryoablation for breast cancer in meeting procedure objectives and patient-specific treatment objectives.We conducted a retrospective analysis of breast cancer patients who underwent breast cryoablation during 2021-2024. Breast radiologists performed outpatient cryoablation using local anesthesia and argon gas cryoprobes under ultrasound or MRI guidance. Patient demographics, referral indications, tumor characteristics, procedure details, and imaging follow-up findings were analyzed. Cryoablation was categorized as curative or palliative. Treatment success was defined as achievement of both procedure and patient-specific treatment objectives.Breast cryoablation was performed for 34 lesions in 29 patients with N0M0 (n = 25), N1M0 (n = 2), N2M0 (n = 1), and N0M1 (n = 1) disease. Most tumors were invasive ductal carcinoma (IDC), low to intermediate grade, estrogen receptor (ER) and progesterone receptor (PR) positive and HER2 negative (23 tumors, 68%). Tumor size ranged from 0.4-1.9 (median 0.8) cm for curative cryoablation and 0.6-6.0 (median 1.3) cm for palliative cryoablation. For 27 patients with follow-up imaging, ablation was curative in 14 patients, 14 tumors and palliative in 13 patients, 18 lesions. Imaging follow-up time ranged from 3 to 26 (median 16) months, > 12 months in 22 of 27 patients and 25 of 32 tumors. Complications were limited to 2 cases of skin frost injury, 1 mild and 1 moderate. Treatment success was achieved in 13 of 14 patients with curative and all 13 patients with palliative cryoablation.Our study defines treatment success for curative and palliative breast cryoablation, demonstrates breast cryoablation achieves not only procedure (technical) but also patient-specific treatment objectives without significant complications, and may serve as guide for integrating breast cryoablation in the treatment of breast cancer patients.Copyright © 2024 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.